Company Overview - Viatris Inc. (VTRS) has a market capitalization of $15.1 billion and operates globally across various regions including North America, Europe, Asia-Pacific, Africa, Latin America, and the Middle East, offering a wide range of branded, generic, complex, and biosimilar medicines [1] Stock Performance - Over the past 52 weeks, VTRS shares have increased by 14.6%, slightly outperforming the S&P 500 Index, which gained 14.3% during the same period [2] - Year-to-date, VTRS stock has returned 5.1%, compared to a 1.4% rise in the S&P 500 Index [2] Financial Performance - In Q3 2025, Viatris reported an adjusted EPS of $0.67 and revenue of $3.76 billion, exceeding expectations; however, shares fell nearly 6% due to a U.S. net loss of $128 million, attributed to a reduction in the fair value of its investment in Biocon Biologics and increased income tax expenses [6] - The decline in adjusted EPS was also influenced by the negative "Indore Impact," leading to an 11% drop compared to Q3 2024 [6] Earnings Forecast - For the fiscal year ending December 2025, analysts project a 12.5% year-over-year growth in adjusted EPS to $2.32 [7] - The earnings surprise history for Viatris is mixed, with the company exceeding consensus estimates in three of the last four quarters [7] Analyst Ratings - Among 10 analysts covering VTRS, the consensus rating is a "Moderate Buy," consisting of four "Strong Buy" ratings, five "Holds," and one "Moderate Sell" [7] - Piper Sandler recently raised Viatris' price target to $12 while maintaining a "Neutral" rating, with a mean price target of $13.33 indicating a 1.8% premium to current price levels [8] - The highest price target of $16 suggests a potential upside of 22.2% from current levels [8]